Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, reported strong results from a prospective, randomized, double-blind, placebo-controlled clinical trial that studied its migraine headache formulation, UBN RELIEF™.
LAS VEGAS, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, reported strong results from a prospective, randomized, double-blind, placebo-controlled clinical trial that studied its migraine headache formulation, UBN RELIEF™. The results were recently published in World Journal of Advanced Research and Reviews.
The study concluded that taking a daily single serving of UBN RELIEF for 60 days can naturally reduce or alleviate symptoms associated with migraines, as well as improve cognitive function, sleep satisfaction and overall quality of life.
The trial demonstrated a reduction of migraine incidents by 53%, decreased length of incidents by 39%, and lowered severity of pain during incidents by 27%. These results were associated with a self-assessed quality of life improvement of 43% and time lost due to migraine incident reduced by 55%.
The results were highly significant given that about one in six Americans or about 55 million people are afflicted with migraine and severe headaches, according to government health studies. Migraine headaches are among the top reasons for emergency room visits, and a high percentage of migraine episodes result in both temporary and long-term disability. This leads to time lost from employment, education, housework, recreation and other important daily activities.
Dr. Gerald M. Haase, clinical professor of surgery at the University of Colorado School of Medicine and Children’s Hospital Colorado, and one of the researchers for the trial, commented: “These strong results clearly demonstrate the ability of UBN RELIEF to alleviate symptoms associated with migraines and improve quality of life when taken on a daily basis for 60 days. Moreover, the conclusions of the study reveal that UBN RELIEF can be a natural alternative for the tens of millions of migraine sufferers. Healthcare providers and consumers can be confident this natural formulation works based on these clinical studies.”
The study also reported that migraineurs have a strong interest in alternative therapies and particularly natural supplements as a means to address their debilitating symptoms. For many, it is the potential side effects of medications that lead to the strong interest in non-pharmaceutical treatments.
“It is important to note that these positive results from UBN RELIEF were achieved without producing any adverse side effects,” stated Healthy Extracts president, Duke Pitts. “Further, we believe such peer-reviewed, published clinical research highly differentiates our products in the marketplace and assures our customers they will see results.”
Independently verified health outcomes also strengthens Healthy Extracts’ direct-to-consumer and distribution marketing efforts, extends its market reach and helps accelerate sales across multiple channels. “In addition to enhancing the confidence and trust of our customers who increasingly subscribe to our UBN products,” continued Pitts, “we see these clinical results opening the door to healthcare providers, pharmacies and specialty stores who place strong emphasis on the independent validation such studies provide.”
The trial results build upon the success of a pilot study which was also published in the World Journal of Advanced Research and Reviews in December 2020. This publication was followed by Healthy Extracts’ expanded study analysis and presentation at the American College of Sports Medicine’s 2021 ACSM Annual Meeting.
UBN RELIEF is based on a specialized version of a Healthy Extracts proprietary, patent-protected formulation. The special formulation is the result of more than 20 years of scientific research, including multiple clinical studies on the key ingredients. The ingredients are naturally derived and contain no caffeine or added sugar.
In addition to severe discomfort and distress, clinical studies have shown that migraines are also related to poor cognitive performance. The key ingredients in UBN RELIEF have been clinically demonstrated to enhance human cognitive behavior and mental focus by improving the functioning of areas of the brain responsible for attention, memory, mood, and reaction times by as much as 46%.
The new trial results provide additional scientific support for Healthy Extracts’ patent protected formulations, and the company has filed an application to the FDA for approval of a qualified health claim regarding the clinical benefits in migraine headaches.
Healthy Extracts’ product research and development is focused on the brain health supplement market that is expected to grow at an 8% compounded annual growth rate (CAGR) to reach $13.4 billion by 2028.
To learn more about RELIEF and Healthy Extracts’ other products, go to tryubn.com/relief and bergametna.com.
About UBN RELIEF
UBN RELIEF is based on a specialized version of a Healthy Extracts proprietary, patent-protected formulation. The special formulation is the result of more than 20 years of scientific research, including multiple clinical studies on the key ingredients. The ingredients are naturally derived and contain no caffeine or added sugar.
Whether as a scoop added to water or coffee, or mixed in a smoothie, RELIEF’s powerful brain activation benefits have been shown to last eight hours or more. The company plans to soon offer RELIEF as a single-serving, bio-degradable gel pack that can be easily consumed anytime, anywhere, no liquid or mixing required.
The company’s proprietary formulation is protected by multiple issued and pending patents. The formulation includes specific highly concentrated medium chain triglycerides (MCTs), which are derived from Healthy Extracts’ patent pending extraction process. MCTs have been shown to elevate the level of ketones in the brain.
The formulation also contains a proprietary blend of other key ingredients, including a naturally sourced nootropic spearmint extract that is clinically demonstrated to support mental focus during the day without disrupting sleep at night; a protective antioxidant found naturally in the body that helps the brain function optimally, and promotes better mood and sleep habits; and a unique natural marigold extract that is scientifically shown to block blue light, enhance brain carotenoid antioxidant levels and replenish lutein, which is critical for optimum eye health.
Learn more about UBN RELIEF or order today at tryubn.com.
About Healthy Extracts “Live Life Young Again”
Healthy Extracts Inc. is a platform for developing or acquiring science-forward, clinically proven, plant-based proprietary products in select high-growth categories within the multibillion-dollar nutraceuticals market.
The company’s subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement containing Citrus Bergamot SuperFruit™. This superfruit is known to have the highest quality and concentration of polyphenols and flavonoids, and with healthy heart benefits backed by more than 17 clinical studies.
UBN KETONOMICS® proprietary formulations have been clinically shown to improve brain health, including memory, cognition, focus and neuro-energy. UBN is pursuing intellectual property license opportunities for monetizing its IP portfolio of multiple issued and pending patents.
For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com.
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K filed with the SEC on February 19, 2021, and future periodic reports filed with the SEC. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.
The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
Food and Drug Administration Disclosure
The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor’s advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.
BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are registered trademarks of Healthy Extracts Inc.™
Healthy Extracts Company Contact
Duke Pitts, President
Healthy Extracts Inc.
Tel (720) 463-1004
Email contact
Investor & Media Contact
Ronald Both or Justin Lumley
CMA Investor & Media Relations
Tel (949) 432-7566
Email contact
Media Contact:
Tim Randall
CMA
Tel (949) 432-7572
Email Contact
A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/0729061f-47e5-4b7e-ba4c-2b431c366de1
UBN RELIEF™
